LLY Stock Recent News
LLY LATEST HEADLINES
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.
Eli Lilly said on Monday that it will acquire a manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines.
Eli Lilly and Novo Nordisk are two of the big names in healthcare focused on a hot GLP-1 drug market. But there's a drug from a smaller biotech which could also prove to be a big player in this area.
The findings add to concerns that GLP-1s could take a bite out of the bottom lines of some of the biggest restaurant companies and packaged food makers.
Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.
Super Micro Computer (SMCI), Eli Lilly (LLY), and Netflix (NFLX) are today's big three stocks. Joel Hawthorne and Ben Lichtenstein discuss how to trade, as well as the technical trends of these names.
When Wall Street tags a stock as a strong buy, it is probably right. Generally speaking, such shares tend to be among the best positioned investments in the market.
Looking ahead to the pharmaceutical earnings season, UBS expressed cautious optimism when looking at several major names. Notably, Eli Lilly and Co (NYSE:LLY), with a 'buy' rating and a price target of $910, is expected to see mixed performance due to shortages of its weightloss drig Mounjaro and Zepbound, though early stocking could partially offset declines in Trulicity sales.
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.